- VETERINARY PRESCRIPTION REQUIRED
- This drug is not approved for human use.
Percorten-V 25 mg/mL, 4 mL Vial is the only FDA-approved medication for treating dogs with primary adrenocortical insufficiency, or Addison's Disease. The main ingredient Desoxycorticosterone Pivalate (DOCP) in Percorten-V pet meds replaces the depleted mineralocorticoid steroids and prevents the buildup of toxic substances in the bloodstream. Percroten-V extends your dog's quality of life if he is suffering from Addison's Disease.
For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
In treating canine hypoadrenocorticism, PERCORTEN-V replaces the mineralocorticoid hormones only. Glucocorticoid replacement must be supplied by small daily doses of glucocorticoid hormones (e.g., prednisone or prednisolone) (0.2 - 0.4 mg/kg/day).
Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy. Begin treatment with PERCORTEN-V at a dose of 1.0 mg per pound of body weight every 25 days. In some patients the dose may be reduced. Serum sodium and potassium levels should be monitored to assure the animal is properly compensated. Most patients are well controlled with a dose range of 0.75 to 1.0 mg per pound of body weight, given every 21 to 30 days.
The well-controlled patient will have normal electrolytes at 14 days after administration or may exhibit slight hyponatremia and hyperkalemia. This needs no additional therapy as long as the patient is active and eating normally. Watch closely for depression, lethargy, vomiting or diarrhea which indicate a probable glucocorticoid deficiency.
At the end of the 25-day dosing interval, the patient should be clinically normal and have normal serum electrolytes. Alternatively, they may have slight hyponatremia and slight hyperkalemia. This constellation of signs indicate that the dosage and dosage interval should not be altered.
If the dog is not clinically normal or serum electrolytes are abnormal, then the dosage interval should be decreased 2-3 days.
Occasionally, dogs on PERCORTEN-V therapy may develop polyuria and polydipsia (PU/PD). This usually indicates excess glucocorticoid, but may also indicate a PERCORTEN-V excess. It is prudent to begin by decreasing the glucocorticoid dose first. If the PU/PD persists, then decrease the dose of PERCORTEN-V without changing the interval between doses.
Before injection, shake the vial thoroughly to mix the microcrystals with the suspension vehicle. PERCORTEN-V suspension is to be injected intramuscularly. Care should be used to prevent inadvertent intravenous injection, which may cause acute collapse and shock. Such animals should receive immediate therapy for shock with intravenous fluids and glucocorticoids.
Some patients are more sensitive to the actions of PERCORTEN-V and may exhibit side effects in an exaggerated degree. Some patients may show signs of hypernatremia or hypokalemia. The dosage of PERCORTEN-V should be reduced in these patients.
Like other adrenocortical hormones, PERCORTEN-V may cause severe side effects if dosage is too high or prolonged. It may cause polyuria, polydipsia, increased blood volume, edema and cardiac enlargement. Excessive weight gain may indicate fluid retention secondary to sodium retention. PERCORTEN-V should be used with caution in patients with congestive heart disease, edema or renal disease.
Not for human use.
Do not use this drug in pregnant dogs. Do not use in dogs suffering from congestive heart disease, severe renal disease or edema.
Keep this and all drugs out of the reach of children. In case of human consumption, contact a physician or Poison Control Center immediately.
Store at room temperature, preferably between 15 and 30°C (59 and 86°F). Protect from light. Protect from freezing.